Sinomab BioScience Ltd. (Sinomab Bio-B) reported no change in its issued share capital for July 2026, ending the month with 1.39 billion ordinary shares in issue and zero treasury shares.

The company confirmed that it remained fully compliant with Hong Kong’s minimum 25% public-float requirement as of 31 July 2026.

Option activity: Under the 2022 Share Option Scheme (approved 26 Oct 2022 and amended 14 Jun 2024), Sinomab granted 18.03 million new options during the month. Outstanding options therefore increased to 87.52 million, while the pool of options still available for future grant stood at 34.02 million shares. No options were exercised in July, no shares were issued, and no funds were raised from option exercises.

No warrants, convertible securities, share repurchases, or other equity movements were reported for the period.

The company’s board affirmed that all activities complied with Hong Kong Listing Rules and relevant regulatory requirements.